CANNABINOID DERIVATIVES
This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in the treatment or prevention of a disease associated with a cannabinoid receptor, including receptors selected from CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.
1 - 98 . (canceled)
99 . A compound having structural formula:
or an enantiomer, diastereomer, racemate, tautomer, or metabolite thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound, enantiomer, diastereomer, racemate, tautomer, or metabolite, wherein the
moiety is
R 1a and R 1b are independently
hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, hydroxy, halo, —O(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —CO 2 H, —CO 2 (C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, -(C 0 -C 4 alkyl)-cycloalkyl, -(C 0 -C 4 alkyl)-heterocycloalkyl, or NR 1c R 1d wherein R 1c and R 1d are independently hydrogen, C 1 -C 4 alkyl, or —C(O)(C 1 -C 4 alkyl), or R 1a and R 1b together with a carbon atom to which they are attached form a cycloalkyl or heterocycloalkyl ring;
R 2 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —(C 0 -C 4 alkyl)-OC(O)O—(C 1 -C 6 alkyl), —OR 2a , —(C 1 -C 4 alkyl)OR 2a , —SR 2a , —(C 1 -C 4 alkyl)SR 2a , —NR 2b R 2c , —(C 1 -C 4 alkyl)NR 2b R 2c , —(C 1 -C 4 alkyl)C(O)NR 2b R 2c , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl, —(C 0 -C 4 alkyl)-heterocycloalkyl, or oxo when attached to a ring of appropriate saturation, wherein R 2a , R 2b , and R 2c are independently hydrogen, C 1 -C 4 alkyl, or —C(O)(C 1 -C 4 ) alkyl;
R 3 is hydrogen, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, —(OCH 2 CH 2 ) 0-6 O(C 1 -C 8 alkyl), —(C 0 -C 4 alkyl)—NR 3a R 3b , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl, wherein R 3a and R 3b are each independently hydrogen or C 1 -C 6 alkyl;
R 4 is —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl; and
R 5 is hydrogen, C 1 -C 8 alkyl, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —(C 1 -C 4 alkyl)C(O)O(C 1 -C 4 alkyl), or —(C 1 -C 4 alkyl)OC(O)(C 1 -C 4 alkyl);
wherein
each alkyl, alkenyl and alkynyl is unsubstituted, halogenated, substituted with one or two hydroxyl or C 1 -C 6 alkoxy groups, or substituted with one or two oxo groups;
each cycloalkyl has 3-10 ring carbons and is saturated or partially unsaturated, and optionally includes one or two fused cycloalkyl rings, each fused ring having 3-8 ring members, and is substituted with 0-6 R 7 ;
each heterocycloalkyl has 3-10 ring members and 1-3 heteroatoms where each is independently boron, nitrogen, oxygen or sulfur and is saturated or partially unsaturated, and optionally includes one or two fused cycloalkyl or aryl rings, each having 3-8 ring members, and is substituted with 0-6 R 7 ;
each aryl is a phenyl or a naphthyl, and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and is substituted with 0-5 R 8 ;
each heteroaryl is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms, where each is independently boron, nitrogen, oxygen or sulfur or a 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms where each is independently boron, nitrogen, oxygen or sulfur, and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and is substituted with 0-5 R 8 ,
in which
each R 7 is independently oxo, C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —C 1 -C 4 alkyl-OR A , —NR B R A , —C 1 -C 4 alkyl-NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2 R A , —S(O) 1-2 NR B R A , —NR B S(O) 1-2 R A , —OCO 2 R A , —OC(O)NR B R A , —NR B CO 2 R A , —NR B C(O)NR B R A , —SCO 2 R A , —OC(O)SR A , —SC(O)SR A , —SC(O)NR B R A , —NR B C(O)SR A , —OC(S)OR A , —OC(S)NR B R A , —NR B C(S)OR A , —NR B C(S)NR B R A , —SC(S)OR A , —OC(S)SR A , —SC(S)SR A , —SC(S)NR B R A , —NR B C(S)SR A , —NR B C(NR B )NR B R A , —NR B S(O) 1-2 NR B R A , unsubstituted phenyl, or a five to six-membered unsubstituted heteroaryl; and
each R 8 is independently optionally-substituted C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —C 1 -C 4 alkyl-OR A , —NR B R A , —C 1 -C 4 alkyl-NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2 R A , —S(O) 1-2 NR B R A , —NR B S(O) 1-2 R A , —OCO 2 R A , —OC(O)NR B R A , —NR B CO 2 R A , —NR B C(O)NR B R A , —SCO 2 R A , —OC(O)SR A , —SC(O)SR A , —SC(O)NR B R A , —NR B C(O)SR A , —OC(S)OR A , —OC(S)NR B R A , —NR B C(S)OR A , —NR B C(S)NR B R A , —SC(S)OR A , —OC(S)SR A , —SC(S)SR A , —SC(S)NR B R A , —NR B C(S)SR A , —NR B C(NR B )NR B R A , —NR B S(O) 1-2 NR B R A , unsubstituted phenyl, or a five to six-membered unsubstituted heteroaryl.
wherein each R A is independently H or C 1 -C 3 alkyl, and each R B is independently H, C 1 -C 3 alkyl, C 1 -C 3 fluoroalkyl, C 1 -C 3 hydroxyalkyl, —S(O) 1-2 (C 1 -C 3 alkyl), —C(O)(C 1 -C 3 alkyl) or —CO 2 (C 1 -C 3 alkyl).
100 . The compound according to claim 99 , wherein the moiety
101 . The compound according to claim 99 , wherein R 1a and R 1b are each independently hydrogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, hydroxy, halo, —O(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —CO 2 (C 1 -C 4 alkyl), —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl.
102 . The compound according to claim 101 , wherein R 1a and R 1b are each independently hydrogen, C 1 -C 4 alkyl, hydroxy, or —CO 2 (C 1 -C 4 alkyl).
103 . The compound according to claim 99 , wherein R 1a is hydrogen and R 1b is —NR 1c R 1d .
104 . The compound according to claim 99 , wherein R 1a and R 1b together with a carbon atom form a cycloalkyl ring comprising 3 to 6 carbon ring members.
105 . The compound according to claim 99 , wherein R 2 is hydrogen, halo, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, —CO 2 H, —(C 0 -C 4 alkyl)-C(O)O(C 1 -C 6 alkyl), —OR 2a , —(C 1 -C 4 alkyl)OR 2a , —SR 2a , —(C 1 -C 4 alkyl)SR 2a , —NR 2b R 2c , —(C 1 -C 4 alkyl)NR 2b R 2c , —(C 1 -C 4 alkyl)C(O)NR 2b R 2c , —(C 0 -C 4 alkyl)-aryl, -(C 0 -C 4 alkyl)-heteroaryl, -(C 0 -C 4 alkyl)-cycloalkyl, -(C 0 -C 4 alkyl)-heterocycloalkyl, or oxo.
106 . The compound according to claim 99 , wherein R 2 is hydrogen, —F, —Cl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, —CO 2 H, hydroxy, —(C 0 -C 2 alkyl)-C(O)O(C 1 -C 6 alkyl), or oxo.
107 . The compound according to claim 99 , wherein R 3 is hydrogen, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, —(OCH 2 CH 2 ) 0-6 OCH 3 , —(C 0 -C 4 alkyl)-aryl, —(C 0 -C 4 alkyl)-heteroaryl, —(C 0 -C 4 alkyl)-cycloalkyl or —(C 0 -C 4 alkyl)-heterocycloalkyl.
108 . The compound according to claim 99 , wherein R 5 is hydrogen, C 1 -C 6 alkyl, —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkyl), —C(O)O(C 1 -C 4 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), or —C(O)N(C 1 -C 4 alkyl) 2 .
109 . The compound according to claim 99 , wherein R 5 is hydrogen, C 1 -C 6 alkyl, or —(C 1 -C 4 alkyl)-O—(C 1 -C 4 alkyl).
110 . The compound according to claim 99 , wherein R 5 is hydrogen.
111 . The compound according to claim 99 , wherein the compound is of formula:
112 . The compound according to claim 99 , wherein R 4 is -(C 0 -C 1 alkyl)-aryl, —(C 0 -C 1 alkyl)-heteroaryl, —(C 0 -C 1 alkyl)-cycloalkyl or —(C 0 -C 1 alkyl)-heterocycloalkyl.
113 . The compound according to claim 99 , wherein R 7 is independently oxo, C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —C 1 -C 4 alkyl-OR A , —NR B R A , —C 1 -C 4 alkyl-NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2 R A , —S(O) 1-2 NR B R A , —NR B S(O) 1-2 R A , unsubstituted phenyl, or a five to six-membered unsubstituted heteroaryl.
114 . The compound according to claim 99 , wherein R 8 is independently C 1 -C 4 alkyl, —Cl, —F, —Br, —CN, —SF 5 , —N 3 , nitro, —SR A , —S(O) 1-2 R A , —OR A , —C 1 -C 4 alkyl-OR A , —NR B R A , —C 1 -C 4 alkyl-NR B R A , —C(O)R A , —C(O)NR B R A , —NR B C(O)R A , —C(S)NR B R A , —NR B C(S)R A , —CO 2 R A , —OC(O)R A , —C(O)SR A , —SC(O)R A , —C(S)OR A , —OC(S)R A , —C(S)SR A , —SC(S)R A , —S(O) 1-2 OR A , —OS(O) 1-2 R A , —S(O) 1-2 NR B R A , —NR B S(O) 1-2 R A , unsubstituted phenyl, or a five to six-membered unsubstituted heteroaryl.
115 . The compound according to claim 99 , which is:
6,6,9-trimethyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pentyl-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)-3-pentyl-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(1H-tetrazol-5-yl)-6H-benzo[c]chromen-1-ol;
5-(1-hydroxy-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-2-yl)-1,3,4-oxadiazol-2(3H)-one;
6,6,9-trimethyl-2-(5-methyl-4H-1,2,4-triazol-3-yl)-3-pentyl-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(1H-pyrrol-3-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(1H-pyrrol-2-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyridin-2-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyrimidin-4-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyrazin-2-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyrimidin-2-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyridin-3-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyrimidin-5-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyridin-4-yl)-6H-benzo[c]chromen-1-ol;
2-(furan-2-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(thiophen-2-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(thiophen-3-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(thiazol-5-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(thiazol-4-yl)-6H-benzo[c]chromen-1-ol;
2-(indolin-2-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol;
2-(1H-benzo[d]imidazol-2-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(9H-purin-8-yl)-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-2-(oxetan-2-yl)-3-pentyl-6H-benzo[c]chromen-1-ol;
6,6, 9-trimethyl-2-(oxetan-3 -yl)-3 -pentyl-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-2-(oxiran-2-yl)-3 -pentyl-6H-benzo[c] chromen-1-ol;
2-(aziridin-2-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol;
2-(aziridin-1-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol;
2-(1H-indol-2-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol
6,6,9-trimethyl-3-pentyl-2-(4-(pyridin-3-yl)phenyl)-6H-benzo[c]chromen-1-ol;
2-(isoxazol-5-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol;
2-(4,5-dihydrooxazol-2-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3 -pentyl-2-(4H-pyran-4-yl)-6H-benzo[c] chromen-1-ol;
6,6,9-trimethyl-2-(1-methyl-1H-pyrazol-5-yl)-3-pentyl-6H-benzo[c]chromen-1-ol;
2-(benzofuran-2-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(1H-pyrazol-4-yl)-6H-benzo[c]chromen-1-ol;
2-(benzo[b]thiophen-2-yl)-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-2-(4-methylthiophen-2-yl)-3 -pentyl-6H-benzo[c] chromen-1-ol;
6,6,9-trimethyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-2-(5-methyl-1,2,4-oxadiazol-3 -yl)-3 -pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c] chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(1H-tetrazol-5-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-2-yl)-1,3,4-oxadiazol-2(3H)-one;
6,6,9-trimethyl-2-(5-methyl-4H-1,2,4-triazol-3 -yl)-3 -pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c] chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(1H-pyrrol-3-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(1H-pyrrol-2-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyridin-2-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyrimidin-4-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6, 9-trimethyl-3 -pentyl-2-(pyrazin-2-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c] chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyrimidin-2-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6, 9-trimethyl-3 -pentyl-2-(pyridin-3 -yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyrimidin-5-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(pyridin-4-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
2-(furan-2-yl)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(thiophen-2-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(thiophen-3-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(thiazol-5-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(thiazol-4-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
2-(indolin-2-yl)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
2-(1H-benzo[d]imidazol-2-yl)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol ;
6,6,9-trimethyl-3-pentyl-2-(9H-purin-8-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6, 9-trimethyl-2-(oxetan-2-yl)-3 -pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c] chromen-1-ol;
6,6, 9-trimethyl-2-(oxetan-3 -yl)-3 -pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c] chromen-1-ol;
6,6,9-trimethyl-2-(oxiran-2-yl)-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
2-(aziridin-2-yl)-6,6,9-trimethyl-3 -pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c] chromen-1-ol;
2-(aziridin-1-yl)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
2-(1H-indol-2-yl)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3 -pentyl-2-(4-(pyridin-3 -yl)phenyl)-6a,7,8,10a-tetrahydro-6H-benzo[c] chromen-1-ol;
2-(isoxazol-5-yl)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
2-(4,5-dihydrooxazol-2-yl)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(4H-pyran-4-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
6,6,9-trimethyl-2-(1-methyl-1H-pyrazol-5-yl)-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
2-(benzofuran-2-yl)-6,6,9-trimethyl-3 -pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c] chromen-1-ol;
6,6,9-trimethyl-3-pentyl-2-(1H-pyrazol-4-yl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol;
2-(benzothiophen-2-yl)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol; or
6,6,9-trimethyl-2-(4-methyl-2-thienyl)-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol.
116 . A pharmaceutical composition comprising a compound of claim 99 , or an enantiomer, diastereomer, racemate, tautomer, or metabolite thereof, or a pharmaceutically acceptable salt, solvate or hydrate of the compound, enantiomer, diastereomer, racemate, tautomer, or metabolite, together with a pharmaceutically acceptable excipient, diluent, or carrier.
117 . A method of treating or preventing a disease associated with cannabinoid receptor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to claim 99 or a pharmaceutical composition thereof.
118 . A method of treating or preventing a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to claim 99 or a pharmaceutical composition thereof, wherein the disease is acute pain, ADHD/ADD, alcohol use disorder, allergic asthma, ALS, Alzheimer's, anorexia, anxiety disorders, social anxiety disorder, specific phobia, test anxiety, generalized anxiety disorder, arthritis, atherosclerosis, autism, bipolar disorder, burns, cancer, cancer pain, Charcot-Marie-Tooth disease, chronic inflammatory demyelinating polyneuropathies, chronic pain, chronic allograft nephropathy, cocaine use disorder, complex regional pain syndrome, congestive heart failure, depression, fibromyalgia, fragile X syndrome/FXTAS, frontotemporal dementias, gingivitis pyrexia, glaucoma, glioblastoma, glomerulonephropathy, Huntington's disease, hypertrophic scars, IBD/IBS, inflammation, Inflammatory myopathies, ischemia, kidney fibrosis, keloids, leukodystrophies, liver fibrosis, liver cirrhosis, lung fibrosis, migraine, multiple sclerosis, myocardial infarction, nausea, neuropathic pain, postherpetic neuralgia, painful diabetic neuropathy, nightmare disorder, non-alcoholic fatty liver disease, obesity, obsessive-compulsive disorder, opioid sparing, opioid use disorder, osteoarthritis, osteoporosis, Parkinson's, post-concussion syndrome/traumatic brain injury, psychosis/schizophrenia, PTSD, regulation of bone mass, REM sleep behaviour disorder, reperfusion injury, Rett syndrome, rheumatoid arthritis, skin conditions, acne, psoriatic arthritis, sleep disorders, insomnia, RLS, spinocerebellar ataxias, systemic fibrosis, systemic sclerosis, thermal injury, tobacco use disorder/nicotine dependence, Tourette's, tumors, or trigeminal neuralgia.